@article{WilsonAmblerLeeetal.2019,
  author    = {Wilson, Duncan and Ambler, Gareth and Lee, Keon-Joo and Lim, Jae-Sung and Shiozawa, Masayuki and Koga, Masatoshi and Li, Linxin and Lovelock, Caroline and Chabriat, Hugues and Hennerici, Michael and Wong, Yuen Kwun and Mak, Henry Ka Fung and Prats-S{\´a}nchez, Luis and Mart{\´i}nez-Dome{\~n}o, Alejandro and Inamura, Shigeru and Yoshifuji, Kazuhisa and Arsava, Ethem Murat and Horstmann, Solveig and Purrucker, Jan and Lam, Bonnie Yin Ka and Wong, Adrian and Kim, Young Dae and Song, Tae-Jin and Schrooten, Maarten and Lemmens, Robin and Eppinger, Sebastian and Gattringer, Thomas and Uysal, Ender and Tanriverdi, Zeynep and Bornstein, Natan M and Ben Assayag, Einor and Hallevi, Hen and Tanaka, Jun and Hara, Hideo and Coutts, Shelagh B and Hert, Lisa and Polymeris, Alexandros and Seiffge, David J and Lyrer, Philippe and Algra, Ale and Kappelle, Jaap and Salman, Rustam Al-Shahi and J{\"a}ger, Hans R and Lip, Gregory Y H and Mattle, Heinrich P and Panos, Leonidas D and Mas, Jean-Louis and Legrand, Laurence and Karayiannis, Christopher and Phan, Thanh and Gunkel, Sarah and Christ, Nicolas and Abrigo, Jill and Leung, Thomas and Chu, Winnie and Chappell, Francesca and Makin, Stephen and Hayden, Derek and Williams, David J and Kooi, M Eline and van Dam-Nolen, Dianne H K and Barbato, Carmen and Browning, Simone and Wiegertjes, Kim and Tuladhar, Anil M and Maaijwee, Noortje and Guevarra, Christine and Yatawara, Chathuri and Mendyk, Anne-Marie and Delmaire, Christine and K{\"o}hler, Sebastian and van Oostenbrugge, Robert and Zhou, Ying and Xu, Chao and Hilal, Saima and Gyanwali, Bibek and Chen, Christopher and Lou, Min and Staals, Julie and Bordet, R{\´e}gis and Kandiah, Nagaendran and de Leeuw, Frank-Erik and Simister, Robert and van der Lugt, Aad and Kelly, Peter J and Wardlaw, Joanna M and Soo, Yannie and Fluri, Felix and Srikanth, Velandai and Calvet, David and Jung, Simon and Kwa, Vincent I H and Engelter, Stefan T and Peters, Nils and Smith, Eric E and Yakushiji, Yusuke and Necioglu Orken, Dilek and Fazekas, Franz and Thijs, Vincent and Heo, Ji Hoe and Mok, Vincent and Veltkamp, Roland and Ay, Hakan and Imaizumi, Toshio and Gomez-Anson, Beatriz and Lau, Kui Kai and Jouvent, Eric and Rothwell, Peter M and Toyoda, Kazunori and Bae, Hee-Yoon and Marti-Fabregas, Joan and Werring, David J},
  title     = {Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies},
  series = {The Lancet Neurology},
  volume    = {18},
  journal   = {The Lancet Neurology},
  organization    = {Microbleeds International Collaborative Network},
  doi       = {10.1016/S1474-4422(19)30197-8},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-233710},
  pages     = {653-665},
  year      = {2019},
  abstract  = {Background Cerebral microbleeds are a neuroimaging biomarker of stroke risk. A crucial clinical question is whether cerebral microbleeds indicate patients with recent ischaemic stroke or transient ischaemic attack in whom the rate of future intracranial haemorrhage is likely to exceed that of recurrent ischaemic stroke when treated with antithrombotic drugs. We therefore aimed to establish whether a large burden of cerebral microbleeds or particular anatomical patterns of cerebral microbleeds can identify ischaemic stroke or transient ischaemic attack patients at higher absolute risk of intracranial haemorrhage than ischaemic stroke. Methods We did a pooled analysis of individual patient data from cohort studies in adults with recent ischaemic stroke or transient ischaemic attack. Cohorts were eligible for inclusion if they prospectively recruited adult participants with ischaemic stroke or transient ischaemic attack; included at least 50 participants; collected data on stroke events over at least 3 months follow-up; used an appropriate MRI sequence that is sensitive to magnetic susceptibility; and documented the number and anatomical distribution of cerebral microbleeds reliably using consensus criteria and validated scales. Our prespecified primary outcomes were a composite of any symptomatic intracranial haemorrhage or ischaemic stroke, symptomatic intracranial haemorrhage, and symptomatic ischaemic stroke. We registered this study with the PROSPERO international prospective register of systematic reviews, number CRD42016036602. Findings Between Jan 1, 1996, and Dec 1, 2018, we identified 344 studies. After exclusions for ineligibility or declined requests for inclusion, 20 322 patients from 38 cohorts (over 35 225 patient-years of follow-up; median 1·34 years [IQR 0·19-2·44]) were included in our analyses. The adjusted hazard ratio [aHR] comparing patients with cerebral microbleeds to those without was 1·35 (95\% CI 1·20-1·50) for the composite outcome of intracranial haemorrhage and ischaemic stroke; 2·45 (1·82-3·29) for intracranial haemorrhage and 1·23 (1·08-1·40) for ischaemic stroke. The aHR increased with increasing cerebral microbleed burden for intracranial haemorrhage but this effect was less marked for ischaemic stroke (for five or more cerebral microbleeds, aHR 4·55 [95\% CI 3·08-6·72] for intracranial haemorrhage vs 1·47 [1·19-1·80] for ischaemic stroke; for ten or more cerebral microbleeds, aHR 5·52 [3·36-9·05] vs 1·43 [1·07-1·91]; and for ≥20 cerebral microbleeds, aHR 8·61 [4·69-15·81] vs 1·86 [1·23-2·82]). However, irrespective of cerebral microbleed anatomical distribution or burden, the rate of ischaemic stroke exceeded that of intracranial haemorrhage (for ten or more cerebral microbleeds, 64 ischaemic strokes [95\% CI 48-84] per 1000 patient-years vs 27 intracranial haemorrhages [17-41] per 1000 patient-years; and for ≥20 cerebral microbleeds, 73 ischaemic strokes [46-108] per 1000 patient-years vs 39 intracranial haemorrhages [21-67] per 1000 patient-years). Interpretation In patients with recent ischaemic stroke or transient ischaemic attack, cerebral microbleeds are associated with a greater relative hazard (aHR) for subsequent intracranial haemorrhage than for ischaemic stroke, but the absolute risk of ischaemic stroke is higher than that of intracranial haemorrhage, regardless of cerebral microbleed presence, antomical distribution, or burden.},
  language  = {en}
}
@article{WaszakNorthcottBuchhalteretal.2018,
  author    = {Waszak, Sebastian M and Northcott, Paul A and Buchhalter, Ivo and Robinson, Giles W and Sutter, Christian and Groebner, Susanne and Grund, Kerstin B and Brugi{\`e}res, Laurence and Jones, David T W and Pajtler, Kristian W and Morrissy, A Sorana and Kool, Marcel and Sturm, Dominik and Chavez, Lukas and Ernst, Aurelie and Brabetz, Sebastian and Hain, Michael and Zichner, Thomas and Segura-Wang, Maia and Weischenfeldt, Joachim and Rausch, Tobias and Mardin, Balca R and Zhou, Xin and Baciu, Cristina and Lawerenz, Christian and Chan, Jennifer A and Varlet, Pascale and Guerrini-Rousseau, Lea and Fults, Daniel W and Grajkowska, Wiesława and Hauser, Peter and Jabado, Nada and Ra, Young-Shin and Zitterbart, Karel and Shringarpure, Suyash S and De La Vega, Francisco M and Bustamante, Carlos D and Ng, Ho-Keung and Perry, Arie and MacDonald, Tobey J and Driever, Pablo Hern{\´a}iz and Bendel, Anne E and Bowers, Daniel C and McCowage, Geoffrey and Chintagumpala, Murali M and Cohn, Richard and Hassall, Timothy and Fleischhack, Gudrun and Eggen, Tone and Wesenberg, Finn and Feychting, Maria and Lannering, Birgitta and Sch{\"u}z, Joachim and Johansen, Christoffer and Andersen, Tina V and R{\"o}{\"o}sli, Martin and Kuehni, Claudia E and Grotzer, Michael and Kjaerheim, Kristina and Monoranu, Camelia M and Archer, Tenley C and Duke, Elizabeth and Pomeroy, Scott L and Shelagh, Redmond and Frank, Stephan and Sumerauer, David and Scheurlen, Wolfram and Ryzhova, Marina V and Milde, Till and Kratz, Christian P and Samuel, David and Zhang, Jinghui and Solomon, David A and Marra, Marco and Eils, Roland and Bartram, Claus R and von Hoff, Katja and Rutkowksi, Stefan and Ramaswamy, Vijay and Gilbertson, Richard J and Korshunov, Andrey and Taylor, Michael D and Lichter, Peter and Malkin, David and Gajjar, Amar and Korbel, Jan O and Pfister, Stefan M},
  title     = {Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort},
  series = {The Lancet Oncology},
  volume    = {19},
  journal   = {The Lancet Oncology},
  doi       = {10.1016/S1470-2045(18)30242-0},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-233425},
  pages     = {785-798},
  year      = {2018},
  abstract  = {Background Medulloblastoma is associated with rare hereditary cancer predisposition syndromes; however, consensus medulloblastoma predisposition genes have not been defined and screening guidelines for genetic counselling and testing for paediatric patients are not available. We aimed to assess and define these genes to provide evidence for future screening guidelines. Methods In this international, multicentre study, we analysed patients with medulloblastoma from retrospective cohorts (International Cancer Genome Consortium [ICGC] PedBrain, Medulloblastoma Advanced Genomics International Consortium [MAGIC], and the CEFALO series) and from prospective cohorts from four clinical studies (SJMB03, SJMB12, SJYC07, and I-HIT-MED). Whole-genome sequences and exome sequences from blood and tumour samples were analysed for rare damaging germline mutations in cancer predisposition genes. DNA methylation profiling was done to determine consensus molecular subgroups: WNT (MBWNT), SHH (MBSHH), group 3 (MBGroup3), and group 4 (MBGroup4). Medulloblastoma predisposition genes were predicted on the basis of rare variant burden tests against controls without a cancer diagnosis from the Exome Aggregation Consortium (ExAC). Previously defined somatic mutational signatures were used to further classify medulloblastoma genomes into two groups, a clock-like group (signatures 1 and 5) and a homologous recombination repair deficiency-like group (signatures 3 and 8), and chromothripsis was investigated using previously established criteria. Progression-free survival and overall survival were modelled for patients with a genetic predisposition to medulloblastoma. Findings We included a total of 1022 patients with medulloblastoma from the retrospective cohorts (n=673) and the four prospective studies (n=349), from whom blood samples (n=1022) and tumour samples (n=800) were analysed for germline mutations in 110 cancer predisposition genes. In our rare variant burden analysis, we compared these against 53 105 sequenced controls from ExAC and identified APC, BRCA2, PALB2, PTCH1, SUFU, and TP53 as consensus medulloblastoma predisposition genes according to our rare variant burden analysis and estimated that germline mutations accounted for 6\% of medulloblastoma diagnoses in the retrospective cohort. The prevalence of genetic predispositions differed between molecular subgroups in the retrospective cohort and was highest for patients in the MBSHH subgroup (20\% in the retrospective cohort). These estimates were replicated in the prospective clinical cohort (germline mutations accounted for 5\% of medulloblastoma diagnoses, with the highest prevalence [14\%] in the MBSHH subgroup). Patients with germline APC mutations developed MBWNT and accounted for most (five [71\%] of seven) cases of MBWNT that had no somatic CTNNB1 exon 3 mutations. Patients with germline mutations in SUFU and PTCH1 mostly developed infant MBSHH. Germline TP53 mutations presented only in childhood patients in the MBSHH subgroup and explained more than half (eight [57\%] of 14) of all chromothripsis events in this subgroup. Germline mutations in PALB2 and BRCA2 were observed across the MBSHH, MBGroup3, and MBGroup4 molecular subgroups and were associated with mutational signatures typical of homologous recombination repair deficiency. In patients with a genetic predisposition to medulloblastoma, 5-year progression-free survival was 52\% (95\% CI 40-69) and 5-year overall survival was 65\% (95\% CI 52-81); these survival estimates differed significantly across patients with germline mutations in different medulloblastoma predisposition genes. Interpretation Genetic counselling and testing should be used as a standard-of-care procedure in patients with MBWNT and MBSHH because these patients have the highest prevalence of damaging germline mutations in known cancer predisposition genes. We propose criteria for routine genetic screening for patients with medulloblastoma based on clinical and molecular tumour characteristics.},
  language  = {en}
}
@article{SchwarzScharfScherpfetal.2019,
  author    = {Schwarz, Christopher and Scharf, Lennart T. and Scherpf, Thorsten and Weismann, Julia and Gessner, Viktoria H.},
  title     = {Isolation of the Metalated Ylides [Ph3P-C-CN]M (M=Li, Na, K): Influence of the Metal Ion on the Structure and Bonding Situation},
  series = {Chemistry - A European Journal},
  volume    = {25},
  journal   = {Chemistry - A European Journal},
  doi       = {10.1002/chem.201805421},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-235445},
  pages     = {2793-2802},
  year      = {2019},
  abstract  = {The isolation and structural characterization of the cyanido-substituted metalated ylides [Ph3P-C-CN]M (1-M; M=Li, Na, K) are reported with lithium, sodium, and potassium as metal cations. In the solid-state, most different aggregates could be determined depending on the metal and additional Lewis bases. The crown-ether complexes of sodium (1-Na) and potassium (1-K) exhibited different structures, with sodium preferring coordination to the nitrogen end, whereas potassium binds in an unusual η2-coordination mode to the two central carbon atoms. The formation of the yldiide was accompanied by structural changes leading to shorter C-C and longer C-N bonds. This could be attributed to the delocalization of the free electron pairs at the carbon atom into the antibonding orbitals of the CN moiety, which was confirmed by IR spectroscopy and computational studies. Detailed density functional theory calculations show that the changes in the structure and the bonding situation were most pronounced in the lithium compounds due to the higher covalency.},
  language  = {en}
}
@article{FaberHudecMalinskyetal.2018,
  author    = {Faber, T. and Hudec, M. and Malinsk{\´y}, M. and Meinzinger, P. and Porod, W. and Staub, F.},
  title     = {A unified leptoquark model confronted with lepton non-universality in B-meson decays},
  series = {Physics Letters B},
  volume    = {787},
  journal   = {Physics Letters B},
  doi       = {10.1016/j.physletb.2018.10.051},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-227419},
  pages     = {159-166},
  year      = {2018},
  abstract  = {The anomalies in the B-meson sector, in particular R-K(*) and R-D(*), are often interpreted as hints for physics beyond the Standard Model. To this end, leptoquarks or a heavy Z' represent the most popular SM extensions which can explain the observations. However, adding these fields by hand is not very satisfactory as it does not address the big questions like a possible embedding into a unified gauge theory. On the other hand, light leptoquarks within a unified framework are challenging due to additional constraints such as lepton flavor violation. The existing accounts typically deal with this issue by providing estimates on the relevant couplings. In this letter we consider a complete model based on the SU(4)(C) circle times SU(2)(L) circle times U(1) R gauge symmetry, a subgroup of SO(10), featuring both scalar and vector leptoquarks. We demonstrate that this setup has, in principle, all the potential to accommodate R-K(*) and R-D(*) while respecting bounds from other sectors usually checked in this context. However, it turns out that K-L -> e(+/-)mu(-/+) severely constraints not only the vector but also the scalar leptoquarks and, consequently, also the room for any sizeable deviations of R-K(*) from 1. We briefly comment on the options for extending the model in order to conform this constraint. Moreover, we present a simple criterion for all-orders proton stability within this class of models.},
  language  = {en}
}
@article{MuentzeGenslerManiucetal.2019,
  author    = {M{\"u}ntze, Jonas and Gensler, Daniel and Maniuc, Octavian and Liu, Dan and Cairns, Tereza and Oder, Daniel and Hu, Kai and Lorenz, Kristina and Frantz, Stefan and Wanner, Christoph and Nordbeck, Peter},
  title     = {Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year},
  series = {Clinical Pharmacology \& Therapeutics},
  volume    = {105},
  journal   = {Clinical Pharmacology \& Therapeutics},
  doi       = {10.1002/cpt.1321},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-231626},
  pages     = {1224-1233},
  year      = {2019},
  abstract  = {Long-term effects of migalastat therapy in clinical practice are currently unknown. We evaluated migalastat efficacy and biomarker changes in a prospective, single-center study on 14 patients with Fabry disease (55 ± 14 years; 11 men). After 1 year of open-label migalastat therapy, patients showed significant changes in alpha-galactosidase-A activity (0.06-0.2 nmol/minute/mg protein; P = 0.001), left ventricular myocardial mass index (137-130 g/m2; P = 0.037), and serum creatinine (0.94-1.0 mg/dL; P = 0.021), accounting for deterioration in estimated glomerular filtration rate (87-78 mL/minute/1.73 m2; P = 0.012). The enzymatic increase correlated with myocardial mass reduction (r = -0.546; P = 0.044) but not with renal function (r = -0.086; P = 0.770). Plasma globotriaosylsphingosine was reduced in therapy-naive patients (10.9-6.0 ng/mL; P = 0.021) and stable (9.6-12.1 ng/mL; P = 0.607) in patients switched from prior enzyme-replacement therapy. These first real-world data show that migalastat substantially increases alpha-galactosidase-A activity, stabilizes related serum biomarkers, and improves cardiac integrity in male and female patients with amenable Fabry disease mutations.},
  language  = {en}
}
@article{GarainShoyamaGinderetal.2024,
  author    = {Garain, Swadhin and Shoyama, Kazutaka and Ginder, Lea-Marleen and S{\´a}rosi, Menyh{\´a}rt and W{\"u}rthner, Frank},
  title     = {The delayed box: biphenyl bisimide cyclophane, a supramolecular nano-environment for the efficient generation of delayed fluorescence},
  series = {Journal of the American Chemical Society},
  volume    = {146},
  journal   = {Journal of the American Chemical Society},
  number    = {31},
  issn      = {0002-7863},
  doi       = {10.1021/jacs.4c07730},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-370385},
  pages     = {22056-22063},
  year      = {2024},
  abstract  = {Activating delayed fluorescence emission in a dilute solution via a non-covalent approach is a formidable challenge. In this report, we propose a strategy for efficient delayed fluorescence generation in dilute solution using a non-covalent approach via supramolecularly engineered cyclophane-based nanoenvironments that provide sufficient binding strength to π-conjugated guests and that can stabilize triplet excitons by reducing vibrational dissipation and lowering the singlet-triplet energy gap for efficient delayed fluorescence emission. Toward this goal, a novel biphenyl bisimide-derived cyclophane is introduced as an electron-deficient and efficient triplet-generating host. Upon encapsulation of various carbazole-derived guests inside the nanocavity of this cyclophane, emissive charge transfer (CT) states close to the triplet energy level of the biphenyl bisimide are generated. The experimental results of host-guest studies manifest high association constants up to 10\(^4\) M\(^{-1}\) as the prerequisite for inclusion complex formation, the generation of emissive CT states, and triplet-state stabilization in a diluted solution state. By means of different carbazole guest molecules, we could realize tunable delayed fluorescence emission in this carbazole-encapsulated biphenyl bisimide cyclophane in methylcyclohexane/carbon tetrachloride solutions with a quantum yield (QY) of up to 15.6\%. Crystal structure analyses and solid-state photophysical studies validate the conclusions from our solution studies and provide insights into the delayed fluorescence emission mechanism.},
  language  = {en}
}
@phdthesis{Dusel2024,
  author    = {Dusel, Marco},
  title     = {Exziton-Polariton-Kondensation in organischen Halbleiter-Mikrokavit{\"a}ten mit hemisph{\"a}rischen Potentiallandschaften},
  doi       = {10.25972/OPUS-37055},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-370554},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Exziton-Polaritonen sind hybride Quasiteilchen, die entstehen durch die starke Kopplung zwischen Halbleiter-Exzitonen und Mikrokavit{\"a}tsphotonen in einem optischen Resonator. Aufgrund ihres bosonischen Charakters k{\"o}nnen die Polaritonen Kondensate ausbilden. In dieser Arbeit ist der emittierende organische Halbleiter das fluoreszierende Protein mCherry. Um einen r{\"a}umlichen Einschluss zu generieren wurden hemisph{\"a}rische Potentiale genutzt. Durch die Variation der Potentiallandschaft (Linse, Molek{\"u}l, Kette, Su-Schrieffer-Heeger-Kette und Honigwaben-Gitter) konnten Eigenschaften wie beispielsweise topologisch nicht-triviale Defekte experimentell bei Umgebungstemperatur demonstriert werden. Zusammengefasst besch{\"a}ftigt sich diese Arbeit mit der Exziton-Polartion Kondensation in unterschiedlichen Potentiallandschaften mit dem organischen Halbleiter mCherry.},
  subject      = {Exziton-Polariton},
  language  = {de}
}
@phdthesis{Drakopoulos2024,
  author    = {Drakopoulos, Antonios},
  title     = {Opioid receptor oligomerization study through fluorescent selective ligands},
  doi       = {10.25972/OPUS-20717},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-207179},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Opioid receptors (ORs) are among the most intensively studied members of the G protein-coupled receptor (GPCR) family due to their important role in pain management and their involvement in psychological and neurological disorders. However, currently available opioid drugs exhibit both serious drawbacks, such as addiction, and life-threatening side effects, such as respiratory depression. Contrary to the classic monomeric model, indirect evidence suggests that ORs might form dimers, which could be endowed with a distinct pharmacological profile, and, thus, be exploited to develop innovative drugs. However, direct evidence for the spontaneous formation of OR dimers in living cells under physiological condition are missing. The focus of this thesis was the design, synthesis and characterization of new, highly subtype-selective OR fluorescent ligands to be used as tools for state-of-the-art microscopy methods, such as single molecule microscopy (SMM), in heterologous cells and potentially in native tissue, in order to investigate OR organization and mobility on the surface of intact, living cells, at low/physiological expression levels. The μOR is the OR subtype which plays the most critical role in pain modulation, while mediating the effects of the most powerful analgesic drugs. Also, it is the OR subtype which is mostly responsible for the major adverse effects of the currently marketed opioid drugs. We aimed to develop a new μOR-selective fluorescent ligand with a potential irreversible binding mode. Although the approach was in principle successful, i.e. the labelled cells were visible and distinguishable; this initial attempt was not suitable for SMM due to the ligands' poor selectivity and affinity as well as due to its high background noise. A second generation of the fluorescent ligand was designed; however the synthesis and characterization are part of another doctoral thesis. Lately, δOR has received attention as a promising drug target, due to its distinct pharmacological profile which features low abuse liability and lack of physical dependence. In addition, δOR expression has been associated with cancer regulation in the periphery, thus further highlighting the interest of imaging tools for this receptor. In this thesis, the development and characterization of two new δOR-selective fluorescent probes with excellent optical properties, based on the well-studied ligand naltrindole (NTI) is presented. Their application in SMM studies is currently underway at the group of Prof. Dr. Davide Calebiro at the University of Birmingham. The κOR is a subtype which has also emerged as a drug target due to its low abuse potential. Despite a growing interest in this receptor, κOR-selective fluorescent probes have been particularly scarce in literature. Herein, the design, synthesis and characterization of the first reported set of fluorescent κOR-selective probes with antagonistic properties, based on the established ligand 5'-guanidinonaltrindole (5'-GNTI) is presented. Two of these were employed for SMM experiments to investigate κOR homodimerization, localization and trafficking. Our findings do not support homodimerization of the κOR-bound probe complexes, while showing that the majority of them follow a normal Brownian diffusion on the cell surface.},
  subject      = {Opioidrezeptor},
  language  = {en}
}
@article{BarkhuizenvanMechelenVermeeretal.2019,
  author    = {Barkhuizen, Melinda and van Mechelen, Ralph and Vermeer, Marijne and Chedraui, Peter and Paes, Dean and van den Hove, Daniel L. A. and Vaes, Bart and Mays, Robert W. and Steinbusch, Harry W. M. and Robertson, Nicola J. and Kramer, Boris W. and Gavilanes, Antonio W. D.},
  title     = {Systemic multipotent adult progenitor cells improve long-term neurodevelopmental outcomes after preterm hypoxic-ischemic encephalopathy},
  series = {Behavioural Brain Research},
  volume    = {362},
  journal   = {Behavioural Brain Research},
  doi       = {10.1016/j.bbr.2019.01.016},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-221506},
  pages     = {77-81},
  year      = {2019},
  abstract  = {There is an urgent need for therapies that could reduce the disease burden of preterm hypoxic-ischemic encephalopathy. Here, we evaluate the long-term effects of multipotent adult progenitor cells (MAPC) on long-term behavioral outcomes in a preterm rat model of perinatal asphyxia. Rats of both sexes were treated with two doses of MAPCs within 24 h after the insult. Locomotor, cognitive and psychiatric impairments were evaluated starting at 1.5 (juvenile) and 6 months (adult). Hypoxia-ischemia affected locomotion, cognition, and anxiety in a sex-dependent manner, with higher vulnerability observed in males. The MAPC therapy partially attenuated deficits in object recognition memory in females of all tested ages, and in the adult males. The hypoxic insult caused delayed hyperactivity in adult males, which was corrected by MAPC therapy. These results suggest that MAPCs may have long-term benefits for neurodevelopmental outcome after preterm birth and global hypoxia-ischemia, which warrants further preclinical exploration.},
  language  = {en}
}
@phdthesis{Korte2024,
  author    = {Korte, Pamela},
  title     = {Die funktionelle Bedeutung des Lipidstoffwechsels f{\"u}r die Stomata{\"o}ffnung bei Hitzestress in \(Arabidopsis\) \(thaliana\)},
  doi       = {10.25972/OPUS-37046},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-370461},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Pflanzen sind verschiedenen Umweltbedingungen ausgesetzt, die zu suboptimalen Wachstumsbedingungen f{\"u}hren k{\"o}nnen. Dies gilt f{\"u}r eine Vielzahl von biotischen und abiotischen Faktoren. In der hier vorgelegten Arbeit wird der Effekt von erh{\"o}hten Temperaturen und Hitze genauer analysiert. Hitze ist einer der wichtigsten abiotischen Stressfaktoren, der das Pflanzenwachstum und die Reproduktion beeinflusst. Viele wichtige Kulturpflanzen zeigen immense Ertragseinbußen, die durch Hitze hervorgerufen werden. Durch den fortschreitenden Klimawandel werden jedoch Hitzeperioden immer h{\"a}ufiger und somit die Folgen f{\"u}r die Nahrungsproduktion immer gravierender. Zur Z{\"u}chtung von Pflanzen die hitzetolerant sind und weniger hohe Ertragseinbußen unter diesem Stress aufweisen, ist es essenziell die grundlegenden molekularen Mechanismen der Hitzetoleranz zu verstehen. Es m{\"u}ssen die verschiedenen physiologischen und biochemischen Prozesse identifiziert werden, die es Pflanzen erm{\"o}glichen, sich anzupassen. Es ist bekannt, dass die Anpassungsmechanismen von Pflanzen komplex sind und sowohl Ver{\"a}nderungen auf zellul{\"a}rer wie auch auf organismischer Ebene beinhalten. Ziel dieser Arbeit war es, weitere Erkenntnisse zu gewinnen, wie diese Anpassung vonstattengeht und welche molekularen Prozesse an ihr beteiligt sind. Ein Hauptaugenmerk lag dabei auf dem Einfluss des Lipidmetabolismus und den daran beteiligten Enzymen. Es konnte bereits gezeigt werden, dass die Akkumulation von Triacylglycerolen bei hohen Temperaturen die basale Thermotoleranz bei Arabidopsis thaliana erh{\"o}ht. Wie jedoch der genaue Mechanismus dieser durch Triacylglycerole vermittelten Thermotoleranz funktioniert, war bis dato nicht bekannt. Ich konnte zeigen, dass die angesammelten Triacylglycerole genutzt werden k{\"o}nnen, um die Stomata w{\"a}hrend des Hitzestress zu {\"o}ffnen. Dies f{\"u}hrt zu einer erh{\"o}hten Transpiration und somit einer K{\"u}hlung der Bl{\"a}tter. Der Abbau von Triacylglycerolen und St{\"a}rke am Morgen ist notwendig, um die Stomata zu {\"o}ffnen. Zus{\"a}tzlich dient der Abbau der Aufrechterhaltung des Citratzyklus und somit der Energieversorgung. In weiteren Experimenten konnte ich durch F{\"u}tterung mit stabil markierter Laurins{\"a}ure zeigen, dass die Triacylglycerole auch dem Aufbau neuer Aminos{\"a}uren unter Stressbedingungen dienen. Die hier vorgestellten Arbeiten bieten die Grundlage, um den Mechanismus der Thermotoleranz besser zu verstehen. Das Verst{\"a}ndnis der in dieser Arbeit beschriebenen molekularen Signalwege und Enzyme kann langfristig dazu beitragen hitzeresistentere Nutzpflanzen zu z{\"u}chten.},
  subject      = {Hitzestress},
  language  = {de}
}
@phdthesis{Brohm2024,
  author    = {Brohm, Katharina Andrea},
  title     = {(Differential-) Diagnostik bei prim{\"a}rem Hyperaldosteronismus: Ermittlung eines LC-MS/MS-spezifischen Aldosterongrenzwerts f{\"u}r den Kochsalzbelastungstest und Evaluation des Orthostasetests hinsichtlich der Differenzierung von Subgruppen},
  doi       = {10.25972/OPUS-36938},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-369382},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Der prim{\"a}re Hyperaldosteronismus (PA) stellt aktuell den h{\"a}ufigsten Grund f{\"u}r das Vorliegen einer sekund{\"a}ren Hypertonie dar. Der in der Best{\"a}tigungsdiagnostik verwendete Kochsalzbelastungstest basiert dabei auf einem fehlenden Absinken der Aldosteronkonzentration im Testverlauf bei Patient:innen mit PA im Vergleich zu Patient:innen mit essentieller Hypertonie (EH). Die Konzentrationsbestimmung erfolgte bisher mittels Immunoassay. Mit der LC-MS/MS steht jedoch mittlerweile eine weitere wichtige analytische Methode in der quantitativen Bestimmung von Steroidhormonen zur Verf{\"u}gung, welche in dieser Arbeit im Hinblick auf den Kochsalzbelastungstest untersucht wurde. Hohe Bedeutung kommt außerdem der Subtypdifferenzierung des PA zu, da die {\"A}tiologie der Erkrankung wegweisend f{\"u}r die Art der Therapie ist. Das Ziel dieser Studie war einerseits die Ermittlung eines LC-MS/MS-spezifischen Aldosteron-Cut-off-Wertes im Kochsalzbelastungstest und die Evaluation des Nutzens der Bestimmung von Steroidprofilen in der Diagnostik des PA. Zum anderen wurde der diagnostische Nutzen des Orthostasetests zur Unterscheidung von unilateraler und bilateraler Genese bei vorliegendem PA untersucht. Im Rahmen dieser Studien wurden 187 bzw. 158 Patient:innen analysiert, die zwischen 2009 und 2019 bei Verdacht auf oder Vorliegen eines PA im Universit{\"a}tsklinikum W{\"u}rzburg vorstellig wurden. Die Diagnose wurde gem{\"a}ß der aktuellen Leitlinie anhand der Ergebnisse des Kochsalzbelastungstests, NNVKs, Bildgebung und postoperativen Outcomes gestellt. Mithilfe der LC-MS/MS wurden erneut die Aldosteronkonzentrationen der aufbewahrten Serumproben des Kochsalzbelastungstests, sowie ein erweitertes Steroidpanel bestimmt. Unter Verwendung einer ROC-Analyse wurden die jeweils bestehenden Cut-off-Werte optimiert bzw. neu ermittelt. Die mittels Immunoassay bestimmten Aldosteronkonzentrationen lagen um 28 ng/L h{\"o}her als die mittels LC-MS/MS bestimmten Konzentrationen. Trotzdem lag der neu ermittelte LC-MS/MS-spezifische Aldosteron-Cut-off-Wert f{\"u}r den Kochsalzbelastungstest bei 69 ng/L und damit h{\"o}her als der f{\"u}r den Immunoassay geltende, optimierte Aldosteron-Cut-off von 54 ng/L. Unter Verwendung des LC-MS/MS- spezifischen Cut-off-Werts erreichte der Kochsalzbelastungstest eine Sensitivit{\"a}t von 78,6\% bei einer Spezifit{\"a}t von 89,3\%. Die Sensitivit{\"a}t des Immunoassay-spezifischen Cut-off-Werts betrug 95,2\% bei einer Spezifit{\"a}t von 86,9\%. Das Bestimmen des gesamten Steroidprofils f{\"u}hrte zu keiner zus{\"a}tzlichen diagnostischen Information bei Durchf{\"u}hrung des Kochsalzbelastungstests. Bei Betrachtung der gesamten Patient:innenkohorte erreichte der Orthostasetest, basierend auf einem Absinken der Plasmaaldosteronkonzentration nach 4h in Orthostase um ≥ 28\% eine Sensitivit{\"a}t von 36,7\% bei einer Spezifit{\"a}t von 100\%. Wurde das Vorliegen eines g{\"u}ltigen Tests (Cortisolabfall nach 4h ≥ 10\%) oder das Vorliegen einer unilateralen Raumforderung in der Bildgebung vorausgesetzt, stieg die Sensitivit{\"a}t des Orthostasetests auf 51,4\% bzw. 51,6\% bei gleichbleibend hoher Spezifit{\"a}t von 100\% an. Abschließend l{\"a}sst sich sagen, dass der Orthostasetest keine Alternative zum NNVK darstellt, jedoch als einfache, nicht invasive Methode der zus{\"a}tzlichen Orientierung zur Untersuchung der {\"A}tiologie des PAs dienen kann. Eine prospektive Evaluation der jeweils neu ermittelten Cut-off-Werte wird notwendig sein, um deren Anwendbarkeit im klinischen Alltag zu {\"u}berpr{\"u}fen. Außerdem k{\"o}nnte die Bestimmung der Hybridsteroide 18-Oxocortisol und 18-Hydroxycortisol wegweisend f{\"u}r die Genese des PA sein.},
  subject      = {Aldosteronismus},
  language  = {de}
}
@article{CzimmererDanielHorvathetal.2018,
  author    = {Czimmerer, Zsolt and Daniel, Bence and Horvath, Attila and R{\"u}ckerl, Dominik and Nagy, Gergely and Kiss, Mate and Peloquin, Matthew and Budai, Marietta M. and Cuaranta-Monroy, Ixchelt and Simandi, Zoltan and Steiner, Laszlo and Nagy Jr., Bela and Poliska, Szilard and Banko, Csaba and Bacso, Zsolt and Schulman, Ira G. and Sauer, Sascha and Deleuze, Jean-Francois and Allen, Judith E. and Benko, Szilvia and Nagy, Laszlo},
  title     = {The Transcription Factor STAT6 Mediates Direct Repression of Inflammatory Enhancers and Limits Activation of Alternatively Polarized Macrophages},
  series = {Immunity},
  volume    = {48},
  journal   = {Immunity},
  doi       = {10.1016/j.immuni.2017.12.010},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-223380},
  pages     = {75-90},
  year      = {2018},
  abstract  = {The molecular basis of signal-dependent transcriptional activation has been extensively studied in macrophage polarization, but our understanding remains limited regarding the molecular determinants of repression. Here we show that IL-4-activated STAT6 transcription factor is required for the direct transcriptional repression of a large number of genes during in vitro and in vivo alternative macrophage polarization. Repression results in decreased lineage-determining transcription factor, p300, and RNA polymerase II binding followed by reduced enhancer RNA expression, H3K27 acetylation, and chromatin accessibility. The repressor function of STAT6 is HDAC3 dependent on a subset of IL-4-repressed genes. In addition, STAT6-repressed enhancers show extensive overlap with the NF-κB p65 cistrome and exhibit decreased responsiveness to lipopolysaccharide after IL-4 stimulus on a subset of genes. As a consequence, macrophages exhibit diminished inflammasome activation, decreased IL-1β production, and pyroptosis. Thus, the IL-4-STAT6 signaling pathway establishes an alternative polarization-specific epigenenomic signature resulting in dampened macrophage responsiveness to inflammatory stimuli.},
  language  = {en}
}
@article{TruebeHertleinMrochenetal.2019,
  author    = {Tr{\"u}be, Patricia and Hertlein, Tobias and Mrochen, Daniel M. and Schulz, Daniel and Jorde, Ilka and Krause, Bettina and Zeun, Julia and Fischer, Stefan and Wolf, Silver A. and Walther, Birgit and Semmler, Torsten and Br{\"o}ker, Barbara M. and Ulrich, Rainer G. and Ohlsen, Knut and Holtfreter, Silva},
  title     = {Bringing together what belongs together: Optimizing murine infection models by using mouse-adapted Staphylococcus aureus strains},
  series = {International Journal of Medical Microbiology},
  volume    = {309},
  journal   = {International Journal of Medical Microbiology},
  doi       = {10.1016/j.ijmm.2018.10.007},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-229081},
  pages     = {26-38},
  year      = {2019},
  abstract  = {Staphylococcus (S.) aureus is a leading cause of bacterial infection world-wide, and currently no vaccine is available for humans. Vaccine development relies heavily on clinically relevant infection models. However, the suitability of mice for S. aureus infection models has often been questioned, because experimental infection of mice with human-adapted S. aureus requires very high infection doses. Moreover, mice were not considered to be natural hosts of S. aureus. The latter has been disproven by our recent findings, showing that both laboratory mice, as well as wild small mammals including mice, voles, and shrews, are naturally colonized with S. aureus. Here, we investigated whether mouse-and vole-derived S. aureus strains show an enhanced virulence in mice as compared to the human-adapted strain Newman. Using a step-wise approach based on the bacterial genotype and in vitro assays for host adaptation, we selected the most promising candidates for murine infection models out of a total of 254 S. aureus isolates from laboratory mice as well as wild rodents and shrews. Four strains representing the clonal complexes (CC) 8, 49, and 88 (n = 2) were selected and compared to the human-adapted S. aureus strain Newman (CC8) in murine pneumonia and bacteremia models. Notably, a bank vole-derived CC49 strain, named DIP, was highly virulent in BALB/c mice in pneumonia and bacteremia models, whereas the other murine and vole strains showed virulence similar to or lower than that of Newman. At one tenth of the standard infection dose DIP induced disease severity, bacterial load and host cytokine and chemokine responses in the murine bacteremia model similar to that of Newman. In the pneumonia model, DIP was also more virulent than Newman but the effect was less pronounced. Whole genome sequencing data analysis identified a pore-forming toxin gene, lukF-PV(P83)/lukM, in DIP but not in the other tested S. aureus isolates. To conclude, the mouse-adapted S. aureus strain DIP allows a significant reduction of the inoculation dose in mice and is hence a promising tool to develop clinically more relevant infection models.},
  language  = {en}
}
@article{TappenbeckSchroederNiebergallRothetal.2019,
  author    = {Tappenbeck, Nils and Schr{\"o}der, Hannes M. and Niebergall-Roth, Elke and Hassinger, Fathema and Dehio, Ulf and Dieter, Kathrin and Kraft, Korinna and Kerstan, Andreas and Esterlechner, Jasmina and Frank, Natasha Y. and Scharffetter-Kochanek, Karin and Murphy, George F. and Orgill, Dennis P. and Beck, Joachim and Frank, Markus H. and Ganss, Christoph and Kluth, Mark A.},
  title     = {In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials},
  series = {Cytotherapy},
  volume    = {21},
  journal   = {Cytotherapy},
  doi       = {10.1016/j.jcyt.2018.12.005},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-240456},
  pages     = {546-560},
  year      = {2019},
  abstract  = {Background aims Human dermal ABCB5-expressing mesenchymal stromal cells (ABCB5+ MSCs) represent a promising candidate for stem cell-based therapy of various currently uncurable diseases in several fields of regenerative medicine. We have developed and validated a method to isolate, from human skin samples, and expand ABCB5+ MSCs that meet the guideline criteria of the International Society for Cellular Therapy. We are able to process these cells into a Good Manufacturing Practice-conforming, MSC-based advanced-therapy medicinal product. Methods To support the development of ABCB5+ MSCs for potential therapeutic topical, intramuscular and intravenous administration, we have tested our product in a series of Good Laboratory Practice-compliant nonclinical in-vivo studies addressing all relevant aspects of biosafety, including potential long-term persistence and proliferation, distribution to nontarget tissues, differentiation into undesired cell types, ectopic tissue formation, tumor formation and local tissue reaction. Results (i) Subcutaneous application of 1 × 107 ABCB5+ MSCs/animal and intravenous application of 2 × 106 ABCB5+ MSCs/animal, respectively, to immunocompromised mice did not result in safety-relevant biodistribution, persistence or proliferation of the cells; (ii) three monthly subcutaneous injections of ABCB5+ MSCs at doses ranging from 1 × 105 to 1 × 107 cells/animal and three biweekly intravenous injections of 2 × 106 ABCB5+ MSCs/animal, respectively, to immunocompromised mice were nontoxic and revealed no tumorigenic potential; and (iii) intramuscular injection of 5 × 106 ABCB5+ MSCs/animal to immunocompromised mice was locally well tolerated. Discussion The present preclinical in vivo data demonstrate the local and systemic safety and tolerability of a novel advanced-therapy medicinal product based on human skin-derived ABCB5+ MSCs.},
  language  = {en}
}
@article{GoettlichKunzZappetal.2018,
  author    = {G{\"o}ttlich, Claudia and Kunz, Meik and Zapp, Cornelia and Nietzer, Sarah L. and Walles, Heike and Dandekar, Thomas and Dandekar, Gudrun},
  title     = {A combined tissue-engineered/in silico signature tool patient stratification in lung cancer},
  series = {Molecular Oncology},
  volume    = {12},
  journal   = {Molecular Oncology},
  doi       = {10.1002/1878-0261.12323},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-233137},
  pages     = {1264-1285},
  year      = {2018},
  abstract  = {Patient-tailored therapy based on tumor drivers is promising for lung cancer treatment. For this, we combined in vitro tissue models with in silico analyses. Using individual cell lines with specific mutations, we demonstrate a generic and rapid stratification pipeline for targeted tumor therapy. We improve in vitro models of tissue conditions by a biological matrix-based three-dimensional (3D) tissue culture that allows in vitro drug testing: It correctly shows a strong drug response upon gefitinib (Gef) treatment in a cell line harboring an EGFR-activating mutation (HCC827), but no clear drug response upon treatment with the HSP90 inhibitor 17AAG in two cell lines with KRAS mutations (H441, A549). In contrast, 2D testing implies wrongly KRAS as a biomarker for HSP90 inhibitor treatment, although this fails in clinical studies. Signaling analysis by phospho-arrays showed similar effects of EGFR inhibition by Gef in HCC827 cells, under both 2D and 3D conditions. Western blot analysis confirmed that for 3D conditions, HSP90 inhibitor treatment implies different p53 regulation and decreased MET inhibition in HCC827 and H441 cells. Using in vitro data (western, phospho-kinase array, proliferation, and apoptosis), we generated cell line-specific in silico topologies and condition-specific (2D, 3D) simulations of signaling correctly mirroring in vitro treatment responses. Networks predict drug targets considering key interactions and individual cell line mutations using the Human Protein Reference Database and the COSMIC database. A signature of potential biomarkers and matching drugs improve stratification and treatment in KRAS-mutated tumors. In silico screening and dynamic simulation of drug actions resulted in individual therapeutic suggestions, that is, targeting HIF1A in H441 and LKB1 in A549 cells. In conclusion, our in vitro tumor tissue model combined with an in silico tool improves drug effect prediction and patient stratification. Our tool is used in our comprehensive cancer center and is made now publicly available for targeted therapy decisions.},
  language  = {en}
}
@article{StromeckiTatariCoudiereMorrisonetal.2018,
  author    = {Stromecki, Margaret and Tatari, Nazanin and Coudi{\`e}re Morrison, Ludivine and Kaur, Ravinder and Zagozewski, Jamie and Palidwor, Gareth and Ramaswamy, Vijay and Skowron, Patryk and W{\"o}lfl, Matthias and Milde, Till and Del Bigio, Marc R. and Taylor, Michael D. and Werbowetski-Ogilvie, Tamra E.},
  title     = {Characterization of a novel OTX2-driven stem cell program in Group 3 and Group 4 medulloblastoma},
  series = {Molecular Oncology},
  volume    = {12},
  journal   = {Molecular Oncology},
  doi       = {10.1002/1878-0261.12177},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-240089},
  pages     = {495-513},
  year      = {2018},
  abstract  = {Medulloblastoma (MB) is the most common malignant primary pediatric brain cancer. Among the most aggressive subtypes, Group 3 and Group 4 originate from stem/progenitor cells, frequently metastasize, and often display the worst prognosis, yet we know the least about the molecular mechanisms driving their progression. Here, we show that the transcription factor orthodenticle homeobox 2 (OTX2) promotes self-renewal while inhibiting differentiation in vitro and increases tumor initiation from MB stem/progenitor cells in vivo. To determine how OTX2 contributes to these processes, we employed complementary bioinformatic approaches to characterize the OTX2 regulatory network and identified novel relationships between OTX2 and genes associated with neuronal differentiation and axon guidance signaling in Group 3 and Group 4 MB stem/progenitor cells. In particular, OTX2 levels were negatively correlated with semaphorin (SEMA) signaling, as expression of 9 SEMA pathway genes is upregulated following OTX2 knockdown with some being potential direct OTX2 targets. Importantly, this negative correlation was also observed in patient samples, with lower expression of SEMA4D associated with poor outcome specifically in Group 4 tumors. Functional proof-of-principle studies demonstrated that increased levels of select SEMA pathway genes are associated with decreased self-renewal and growth in vitro and in vivo and that RHO signaling, known to mediate the effects of SEMA genes, is contributing to the OTX2 KD phenotype. Our study provides mechanistic insight into the networks controlled by OTX2 in MB stem/progenitor cells and reveals novel roles for axon guidance genes and their downstream effectors as putative tumor suppressors in MB.},
  language  = {en}
}
@article{HoeniglOraschFaserletal.2019,
  author    = {Hoenigl, Martin and Orasch, Thomas and Faserl, Klaus and Prattes, Juergen and Loeffler, Juergen and Springer, Jan and Gsaller, Fabio and Reischies, Frederike and Duettmann, Wiebke and Raggam, Reinhard B. and Lindner, Herbert and Haas, Hubertus},
  title     = {Triacetylfusarinine C: A urine biomarker for diagnosis of invasive aspergillosis},
  series = {Journal of Infection},
  volume    = {78},
  journal   = {Journal of Infection},
  doi       = {10.1016/j.jinf.2018.09.006},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-320939},
  pages     = {150-157},
  year      = {2019},
  abstract  = {Objectives Early diagnosis of invasive aspergillosis (IA) remains challenging, with available diagnostics being limited by inadequate sensitivities and specificities. Triacetylfusarinine C, a fungal siderophore that has been shown to accumulate in urine in animal models, is a potential new biomarker for diagnosis of IA. Methods We developed a method allowing absolute and matrix-independent mass spectrometric quantification of TAFC. Urine TAFC, normalized to creatinine, was determined in 44 samples from 24 patients with underlying hematologic malignancies and probable, possible or no IA according to current EORTC/MSG criteria and compared to other established biomarkers measured in urine and same-day blood samples. Results TAFC/creatinine sensitivity, specificity, positive and negative likelihood ratio for probable versus no IA (cut-off ≥ 3) were 0.86, 0.88, 6.86, 0.16 per patient. Conclusion For the first time, we provide proof for the occurrence of TAFC in human urine. TAFC/creatinine index determination in urine showed promising results for diagnosis of IA offering the advantages of non-invasive sampling. Sensitivity and specificity were similar as reported for GM determination in serum and bronchoalveolar lavage, the gold standard mycological criterion for IA diagnosis.},
  language  = {en}
}
@article{HeimannPenackHeinzetal.2019,
  author    = {Heimann, Sebastian M. and Penack, Olaf and Heinz, Werner J. and Rachow, Tobias and Egerer, Gerlinde and Kessel, Johanna and Claßen, Annika Y. and Vehreschild, J{\"o}rg Janne},
  title     = {Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals},
  series = {International Journal of Infectious Diseases},
  volume    = {83},
  journal   = {International Journal of Infectious Diseases},
  doi       = {10.1016/j.ijid.2019.04.006},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-319567},
  pages     = {130-138},
  year      = {2019},
  abstract  = {Objectives Novel formulations (gastro-resistant tablet and intravenous solution) of posaconazole (POS) have been approved in prophylaxis and therapy of invasive fungal diseases (IFDs). Study aim was to analyze treatment strategies and clinical effectiveness. Methods We set up a web-based registry on www.ClinicalSurveys.net for documentation of comprehensive data of patients who received novel POS formulations. Data analysis was split into two groups of patients who received novel POS formulations for antifungal prophylaxis (posaconazole prophylaxis group) and antifungal therapy (posaconazole therapy group), respectively. Results Overall, 180 patients (151 in the posaconazole prophylaxis group and 29 in the posaconazole therapy group) from six German tertiary care centers and hospitalized between 05/2014 - 03/2016 were observed. Median age was 58 years (range: 19 - 77 years) and the most common risk factor for IFD was chemotherapy (n = 136; 76\%). In the posaconazole prophylaxis group and posaconazole therapy group, median POS serum levels at steady-state were 1,068 μg/L (IQR 573-1,498 μg/L) and 904 μg/L (IQR 728-1,550 μg/L), respectively (P = 0.776). During antifungal prophylaxis with POS, nine (6\%) probable/proven fungal breakthroughs were reported and overall survival rate of hospitalization was 86\%. The median overall duration of POS therapy was 18 days (IQR: 7 - 23 days). Fourteen patients (48\%) had progressive IFD under POS therapy, of these five patients (36\%) died related to or likely related to IFD. Conclusions Our study demonstrates clinical effectiveness of antifungal prophylaxis with novel POS formulations. In patients treated for possible/probable/proven IFD, we observed considerable mortality in patients receiving salvage treatment and with infections due to rare fungal species.},
  language  = {en}
}
@article{StoreyStaplinHaynesetal.2018,
  author    = {Storey, Benjamin C. and Staplin, Natalie and Haynes, Richard and Reith, Christina and Emberson, Jonathan and Herrington, William G. and Wheeler, David C. and Walker, Robert and Fellstr{\"o}m, Bengt and Wanner, Christoph and Landray, Martin J. and Baigent, Colin},
  title     = {Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation},
  series = {Kidney International},
  volume    = {93},
  journal   = {Kidney International},
  organization    = {The SHARP Collaborative Group},
  doi       = {10.1016/j.kint.2017.09.011},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-240067},
  pages     = {1000-1007},
  year      = {2018},
  abstract  = {Markers of inflammation, including plasma C-reactive protein (CRP), are associated with an increased risk of cardiovascular disease, and it has been suggested that this association is causal. However, the relationship between inflammation and cardiovascular disease has not been extensively studied in patients with chronic kidney disease. To evaluate this, we used data from the Study of Heart and Renal Protection (SHARP) to assess associations between circulating CRP and LDL cholesterol levels and the risk of vascular and non-vascular outcomes. Major vascular events were defined as nonfatal myocardial infarction, cardiac death, stroke or arterial revascularization, with an expanded outcome of vascular events of any type. Higher baseline CRP was associated with an increased risk of major vascular events (hazard ratio per 3x increase 1.28; 95\% confidence interval 1.19-1.38). Higher baseline LDL cholesterol was also associated with an increased risk of major vascular events (hazard ratio per 0.6 mmol/L higher LDL cholesterol; 1.14, 1.06-1.22). Higher baseline CRP was associated with an increased risk of a range of non-vascular events (1.16, 1.12-1.21), but there was a weak inverse association between baseline LDL cholesterol and non-vascular events (0.96, 0.92-0.99). The efficacy of lowering LDL cholesterol with simvastatin/ezetimibe on major vascular events, in the randomized comparison, was similar irrespective of CRP concentration at baseline. Thus, decisions to offer statin-based therapy to patients with chronic kidney disease should continue to be guided by their absolute risk of atherosclerotic events. Estimation of such risk may include plasma biomarkers of inflammation, but there is no evidence that the relative beneficial effects of reducing LDL cholesterol depends on plasma CRP concentration.},
  language  = {en}
}
@article{ZhangYeGburecketal.2018,
  author    = {Zhang, Zishuai and Ye, Siyu and Gbureck, Uwe and Barralet, Jake E. and Merle, G{\´e}raldine},
  title     = {Cavitation Mediated 3D Microstructured Architectures from Nanocarbon},
  series = {Advanced Functional Materials},
  volume    = {28},
  journal   = {Advanced Functional Materials},
  doi       = {10.1002/adfm.201706832},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-233926},
  year      = {2018},
  abstract  = {Here, the formation of high surface area microscale assemblies of nanocarbon through phosphate and ultrasound cavitation treatment is reported. Despite high conductivity and large surface area, potential health and safety concerns limit the use of nanocarbon and add challenges to handling. Previously, it is shown that phosphate ultrasonic bonding is ineffective for organic materials but in this study, it is found that by a preliminary oxidizing treatment, several carbons can be readily assembled from xerogels. Assembling nanocarbon into microparticles can usually require a binder or surfactants, which can reduce surface area or conductivity and generate a low microsphere yield. Carbon nanotube microspheres are nitrogen-doped and flower-like nanostructured Pt deposited on their surface, and finally showcased as efficient cathode electrocatalysts for the oxygen reduction reaction (half-wave potential 0.78 V vs reversible hydrogen electrode) and methanol oxidation (417 mA mg-1). In particular, no significant degradation of the catalysts is detected after 12 000 cycles (26.6 h). These results indicate the potential of this multimaterial assembly method and open a new way to improve handling of nanoscale materials.},
  language  = {en}
}